Novo Nordisk Loses US Court Ruling Over Eli Lilly Weight-Loss Drug Ads

The ruling is a procedural win for Eli Lilly in the obesity-drug rivalry, but its practical weight is unclear because the terms were not disclosed. What matters is that Novo Nordisk's attempt to use the courts to constrain a rival's promotional claims did not succeed, leaving the competitive contest to play out through marketing and clinical differentiation rather than legal restriction. Whether this shifts the advertising tactics of either company, or prompts further litigation, is the open question.